Patents Assigned to ETABLISSEMENT FRANÇAIS DU SANG
-
Publication number: 20240075097Abstract: Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.Type: ApplicationFiled: December 27, 2022Publication date: March 7, 2024Applicants: UNIVERSITE TOULOUSE III-PAUL SABATIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANÇAIS DU SANGInventors: Jean-Philippe COMBIER, Anne PREL, Frédéric DESCHASEAUX
-
Patent number: 11903982Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.Type: GrantFiled: May 10, 2022Date of Patent: February 20, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANCAIS DU SANG (EFS), UNIVERSITE DE BRETAGNE OCCIDENTALE, CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BRESTInventors: Rozenn Le Berre, Marie-Sarah Fangous, Gwenaelle Le Blay, Geneviève Hery-Arnaud, Rosyne Lagrafeuille
-
Patent number: 11839630Abstract: The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.Type: GrantFiled: November 14, 2018Date of Patent: December 12, 2023Assignees: ETABLISSEMENT FRANCAIS DU SANG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE, CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON, UNIVERSITE DE FRANCHE COMTEInventors: Christophe Ferrand, Marina Deschamps, Fabrice Larosa
-
Patent number: 11793865Abstract: A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.Type: GrantFiled: April 14, 2020Date of Patent: October 24, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE BESANCONInventors: Sylvain Perruche, Philippe Saas, Francis Bonnefoy
-
Patent number: 11773163Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.Type: GrantFiled: November 21, 2017Date of Patent: October 3, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE STRASBOURG, ETABLISSEMENT FRANçAIS DU SANG (EFS)Inventors: Pierre Mangin, Christian Gachet
-
Publication number: 20230279355Abstract: The method for the in vitro or ex vivo amplification of stem cells of brown or beige adipocytes includes: extracting (i) a stromal vascular fraction from human adipose tissue including endothelial cells of the vascular network of human adipose tissue and stem cells of brown or beige human adipose tissue and (ii) an extracellular matrix of the human adipose tissue, the extracellular matrix including endothelial cells of the vascular network of human adipose tissue, stem cells of brown or beige human adipose tissue and collagen; mixing the stromal vascular fraction and the extracellular matrix; and culturing the mixture obtained, in suspension, in a culture medium.Type: ApplicationFiled: July 15, 2021Publication date: September 7, 2023Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CHU DE NICE, ETABLISSEMENT FRANCAIS DU SANG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE COTE D'AZUR, UNIVERSITE TOULOUSE III - PAUL SABATIERInventors: Christian, Jean, Lucien Dani, Vincent Dani, Louis Casteilla, Alain, Pierre, Louis Doglio, Philippe Letertre
-
Patent number: 11607443Abstract: Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.Type: GrantFiled: December 22, 2017Date of Patent: March 21, 2023Assignees: UNIVERSITE TOULOUSE III-PAUL SABATIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANçAIS DU SANGInventors: Jean-Philippe Combier, Anne Prel, Frédéric Deschaseaux
-
Patent number: 11589575Abstract: The present invention relates to a solution for the preservation of cells from placental blood, from bone marrow and from peripheral blood.Type: GrantFiled: September 9, 2016Date of Patent: February 28, 2023Assignees: ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITÉ DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Zoran Ivanovic, Jean Chevaleyre, Laura Rodriguez, Esther Attebi
-
Publication number: 20220348668Abstract: The invention is relative to monoclonal anti-CD123 antibodies, or fragments thereof that specifically bind to the alpha chain of the human interleukin 3 (IL3) receptor. Further, the invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or an antibody fragment which includes an anti-CD123 binding domain, a transmembrane domain, and an intracellular signaling domain comprising at least a stimulatory domain, polypeptides encoded by said nucleic acid molecule as well as an isolated chimeric antigen receptor (CAR) molecules comprising such an antibody or antibody fragment. The invention is also relative to a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising said vector, and to the use of a T cell expressing a CAR molecule for a treatment of a proliferative disease in a mammal, such as cancer.Type: ApplicationFiled: June 22, 2020Publication date: November 3, 2022Applicants: UNIVERSITE DE FRANCHE-COMTE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ETABLISSEMENT FRANÇAIS DU SANG, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANÇONInventors: Francine GARNACHE-OTTOU, Christophe FERRAND, Fanny ANGELOT-DELETTRE, Marina DESCHAMPS, Elodie BOLE-RICHARD, Olivier ADOTEVI
-
Patent number: 11458118Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.Type: GrantFiled: April 20, 2018Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BRETAGNE OCCIDENTALE, ETABLISSEMENT FRANÇAIS DU SANG (EFS), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BRESTInventors: Pascal Trouve, Claude Ferec, Mathieu Kerbiriou, Florentin Huguet
-
Patent number: 11390643Abstract: The present invention relates to a modified oligonucleotide having two or more thiol functions, which can be immobilized on a gold surface or on a grafted surface, in particular a surface comprising at least one carbon-carbon double bond or carbon-carbon triple bond or haloacetamide functions, preferably maleimide or acrylamide functions. The invention also relates to a method for detecting a nucleic acid in a biological sample comprising a step of detecting hybridization between a modified oligonucleotide and a target nucleic acid amplified from the biological sample. The invention relates more particularly to a method for detecting, genotyping or sequencing a pathogenic organism, preferably a virus.Type: GrantFiled: February 8, 2019Date of Patent: July 19, 2022Assignees: ETABLISSEMENT FRANÇAIS DU SANG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE MONTPELLIER, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Chantal Fournier-Wirth, Myriam Lereau, Jean-François Cantaloube, Jean-Jacques Vasseur, François Morvan, Albert Meyer, Julie Mayen, Carole Chaix, Carole Farre
-
Patent number: 11364271Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.Type: GrantFiled: April 19, 2019Date of Patent: June 21, 2022Assignees: INSERM, Etablissement Français Du Sang (EFS), Université De Bretagne Occidentale, Centre Hospitalier Regional et Universitaire de BrestInventors: Rozenn Le Berre, Marie-Sarah Fangous, Gwenaelle Le Blay, Geneviève Hery-Arnaud, Rosyne Lagrafeuille
-
Publication number: 20220168232Abstract: A capsule including alginate encapsulating: insulin-secreting cells, a RGD-alginate, mesenchymal stem cells, extracellular matrix, the process for the preparation thereof and the use thereof for treating diabetes.Type: ApplicationFiled: March 27, 2020Publication date: June 2, 2022Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE GRENOBLE ALPES, ETABLISSEMENT FRANCAIS DU SANG, WAKE FOREST UNIVERSITY HEALTH SCIENCESInventors: Sandrine LABLANCHE, Pierre-Yves BENHAMOU, Emily TUBBS, Anaïck MOISAN, Harald EGELHOFER, Virginie PERSOONS, Florence RIVERA, Frédéric BOTTAUSCI, Maxime PIERRON, Giuseppe ORLANDO, Riccardo TAMBURRINI
-
Patent number: 11248261Abstract: The present invention relates to the identification of a novel allele of the RHD gene associated with a weak D phenotype and the kits and methods for detecting this allele.Type: GrantFiled: March 7, 2018Date of Patent: February 15, 2022Assignees: ETABLISSEMENT FRANCAIS DU SANG, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY, UNIVERSITE DE BRETAGNE OCCIDENTALE (UBO)Inventors: Yann Fichou, Swati Kulkarni
-
Patent number: 11231427Abstract: The invention concerns a method for determining, by flow cytometry, the hemoglobin F (HbF) content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the HbF content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or ?-thalassemia.Type: GrantFiled: November 3, 2017Date of Patent: January 25, 2022Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUT NATIONAL DE LA SANTE ET DE RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Marie Cambot, Gaetana Vandemeulebrouck, France Noizat Pirenne, Pablo Bartolucci, Marie Georgine Rakotoson, Frédéric Galacteros, Nicolas Hebert
-
Patent number: 11225684Abstract: The present invention relates to a method for genotyping single nucleotide polymorphisms (SNPs) using a lateral flow test device. The invention also relates to a kit comprising said lateral flow test device and also to the use thereof for genotyping single nucleotide polymorphisms (SNPs).Type: GrantFiled: September 9, 2016Date of Patent: January 18, 2022Assignee: ETABLISSEMENT FRANCAIS DU SANGInventors: Jean-Charles Bres, Julien Gomez-Martinez
-
Patent number: 11078229Abstract: The present invention relates to a thiol compound suitable for forming a chain of oligomers that can be grafted to an oligonucleotide. The invention also relates to an oligonucleotide grafted by such a compound, thus having one or more thiol functions, suitable for being immobilized on a gold surface or on a grafted surface.Type: GrantFiled: January 4, 2018Date of Patent: August 3, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ETABLISSEMENT FRANCAIS DU SANGInventors: François Morvan, Albert Meyer, Jean-Jacques Vasseur, Julie Mayen, Carole Chaix, Carole Farre, Chantal Fournier-Wirth, Jean-François Cantaloube, Myriam Lereau
-
Publication number: 20210077732Abstract: A sealed and cryoresistant device for injecting a solution, the device being designed to be associated with a needle for subsequent injection of the solution and including an injection body, a plug and a plunger head. The injection body includes a first, proximal end closed in a sealed manner by the plunger head and a second, distal end closed in a sealed manner by the plug. The plug is held on the injection body by a fastening and includes a breakable portion allowing a needle to be mounted, the plug being a divisible plug, the separation of a divisible portion releasing an element for fastening an injector including a needle. The materials forming the device are cryoresistant.Type: ApplicationFiled: December 14, 2018Publication date: March 18, 2021Applicant: ÉTABLISSEMENT FRANÇAIS DU SANGInventor: Harald EGELHOFER
-
Publication number: 20200237884Abstract: A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.Type: ApplicationFiled: April 14, 2020Publication date: July 30, 2020Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCONInventors: Sylvain PERRUCHE, Philippe SAAS, Francis BONNEFOY
-
Patent number: 10660329Abstract: The present invention relates to a method for preserving, preferably human, cells, tissues or organs in severe hypothermia, comprising a step during which the cells, tissues or organs are kept in moderate hypothermia and preferably in a hypoxic and/or hypercapnic atmosphere, before placing them in severe hypothermia.Type: GrantFiled: April 22, 2016Date of Patent: May 26, 2020Assignees: ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITÉ DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Zoran Ivanovic, Sandie Gerby, Marija Vlaski-Lafarge